Reviva Pharmaceuticals’ (RVPH) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a research note released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $4.00 price target on the stock. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.32) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.25) EPS.

A number of other research analysts have also commented on RVPH. D. Boral Capital restated a “buy” rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday. Chardan Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. Benchmark reduced their price objective on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a report on Monday, September 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Reviva Pharmaceuticals to a “sell” rating in a research report on Saturday, October 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $3.86.

Reviva Pharmaceuticals Stock Performance

Shares of RVPH opened at $0.28 on Tuesday. Reviva Pharmaceuticals has a 52 week low of $0.25 and a 52 week high of $2.17. The firm has a market capitalization of $32.68 million, a P/E ratio of -0.62 and a beta of -0.02. The company has a 50-day simple moving average of $0.56 and a 200-day simple moving average of $0.51.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.05. As a group, equities analysts forecast that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Institutional Trading of Reviva Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in shares of Reviva Pharmaceuticals during the second quarter worth approximately $31,000. Lido Advisors LLC bought a new stake in Reviva Pharmaceuticals during the 3rd quarter worth approximately $37,000. NewEdge Advisors LLC bought a new stake in Reviva Pharmaceuticals during the 1st quarter worth approximately $58,000. Geode Capital Management LLC increased its holdings in Reviva Pharmaceuticals by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares in the last quarter. Finally, Persistent Asset Partners Ltd raised its position in Reviva Pharmaceuticals by 300.0% in the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after purchasing an additional 480,864 shares during the last quarter. 63.18% of the stock is owned by institutional investors.

Key Reviva Pharmaceuticals News

Here are the key news stories impacting Reviva Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright materially improved near‑term loss forecasts and reiterated a Buy with a $4.00 target — the firm raised FY2025 EPS to ($0.32) from ($0.42), lifted multiple quarterly estimates (many to ($0.06) EPS), and raised FY2026 to ($0.25) from ($0.29). The $4.00 target implies very large upside from current levels, which can attract retail and momentum buyers. HC Wainwright Upgrades
• Positive Sentiment: Unusually large call‑option activity — traders bought ~25,745 call contracts (≈295% above normal volume) — signals speculative bullish positioning and can amplify intraday moves as market‑makers hedge. Options Activity
• Positive Sentiment: D. Boral Capital reiterated a Buy rating on RVPH, providing additional analyst support that can sustain buying interest. D. Boral Capital Reiterate
• Neutral Sentiment: Reported short‑interest data is anomalous/zero in the public release (shows 0 shares / NaN change), so it offers little reliable signal about bearish positioning or potential short‑squeeze dynamics at this time.
• Negative Sentiment: Roth Capital cut its price target to $1.50 from $3.00, a noteworthy downgrade relative to the $4.00 target from HC Wainwright; divergent analyst targets increase uncertainty and can pressure the stock. Roth Capital Cut

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.